home / stock / amrx / amrx articles
Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported fourth-quarter 2023 revenues of $616.98 million, up 1% Y/Y, missing the co...
PHILADELPHIA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Am...
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's ...
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's s...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Company launches generic equivalent to OTC NARCAN ® Nasal Spray Provides convenient, affordable access to life-saving medicine Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the availability of Over th...
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forw...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. Th...